<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221231</url>
  </required_header>
  <id_info>
    <org_study_id>131115</org_study_id>
    <nct_id>NCT03221231</nct_id>
  </id_info>
  <brief_title>N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms</brief_title>
  <official_title>N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of repeated NAC administration on glutamate&#xD;
      concentrations in the anterior cingulate cortex (ACC), on neurocognitive functioning, and on&#xD;
      neuro-inflammatory parameters in adult cannabis-dependent individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain glutamate concentrations</measure>
    <time_frame>at study end (2 weeks after study start)</time_frame>
    <description>Glutamate concentrations in the anterior cingulate cortex (ACC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor impulsivity</measure>
    <time_frame>at study end (2 weeks after study start)</time_frame>
    <description>Stop Signal Reaction Time (SSRT) on the Stop Signal Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive impulsivity</measure>
    <time_frame>at study end (2 weeks after study start)</time_frame>
    <description>Indifference point measured by a Monetary Delayed Discounting Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attentional Bias</measure>
    <time_frame>at study end (2 weeks after study start)</time_frame>
    <description>Difference in response time for incongruent-congruent stimuli on a Stroop task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuro-inflammation</measure>
    <time_frame>at study end (2 weeks after study start)</time_frame>
    <description>Concentration of interleukin in blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>1200 mg/day, twice daily, N-acetylcysteine</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>twice daily, placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive measures</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuro-inflammatory measures</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current DSM-IV diagnosis of cannabis dependence, &gt;1 week detoxified and abstinent;&#xD;
&#xD;
          -  Able to provide written informed consent and to comply with study procedures.&#xD;
&#xD;
          -  Dutch speaking (Dutch as primary language).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently dependent on any substance other than cannabis, alcohol or nicotine;&#xD;
&#xD;
          -  History of any major internal disease (including diabetes, cardiovascular disease,&#xD;
             lung disease, liver or kidney disease);&#xD;
&#xD;
          -  An active or any history of neurological disorder, including but not limited to&#xD;
             seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head&#xD;
             trauma with prolonged loss of consciousness (&gt;10 minutes), or migraine headaches;&#xD;
&#xD;
          -  An active or a history of a psychiatric disorder including, but not limited to,&#xD;
             depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;&#xD;
&#xD;
          -  Asthma;&#xD;
&#xD;
          -  Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy&#xD;
             with medication that could interact adversely with n-acetylcysteine within 30 days&#xD;
             prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs,&#xD;
             anti-coagulants);&#xD;
&#xD;
          -  Exclusion criteria for MRI: having metal in the body and/or having claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cleo L Crunelle, PhD</last_name>
    <email>nacstudie@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>F Matthys PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cleo L Crunelle, PhD</last_name>
      <email>nacstudie@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

